Annika K. Martin to Discuss the USC Tyndall Sexual Abuse Class Action Lawsuit at Berkeley Law

On Thursday, January 23, 2020, from 12:40 – 2:00 p.m., Lieff Cabraser partner Annika K. Martin will speak at Berkeley Law’s Lunch Talk event on the USC Tyndall Sex Abuse Litigation, in which Ms. Martin represents women who were sexually abused, harassed, and molested by former head USC gynecologist George Tyndall, M.D. while they were

2020-01-21T15:28:09+00:00January 21st, 2020|Firm News, Sexual Abuse|

Elizabeth Cabraser, Paulina do Amaral, and Annika K. Martin to Serve as Faculty in March 2020 Duke University Mass Tort MDL Certificate Program

The Duke Law School Bolch Judicial Institute is holding an intensive 3-day mass-tort MDL instructional program from March 11-13, 2020. Faculty will include two Duke Law professors, six experienced MDL judges, and 25 lawyers who have either served as preeminent mass-tort lead counsel or chaired specific-task MDL committees. The program is designed for both plaintiff and defense

2020-01-10T12:56:56+00:00January 10th, 2020|Firm News|

Lieff Cabraser Names New Partners for 2020

We are proud to announce that Andrew Kaufman, Kelly McNabb, John Nicolaou, and Tiseme Zegeye have been promoted to partner. Andrew, who works in our Nashville office, has a practice that focuses on financial fraud, consumer protection, and product defect cases. John and Kelly are located in New York City, where John works on securities

2022-09-21T17:44:15+00:00January 1st, 2020|Firm News|

Plaintiffs Secure $35M Settlement With Momenta Pharma in Lovenox Blood Clot Drug Antitrust Class Action

As reported by Law360 (subscription), the parties in the Lovenox/Enox blood clot drug antitrust lawsuit have announced a $35 million settlement in the class action lawsuit brought on behalf of thousands of buyers of generic Lovenox (enoxaparin) that accused the company and Sandoz Pharmaceuticals of illegally conspiring to prevent other drug companies from competing in the

2019-12-12T12:44:18+00:00December 12th, 2019|Antitrust, Firm News|